Intelligence Feed

The strangest thing about the peptide boom is that branding is scaling faster than the science. The same molecule gets repackaged as a recovery tool, longevity hack, cosmetic ingredient, or “metabolic reset” depending on who is selling it. At this point the label seems to decide the mechanism. Give it six months and every peptide will have a lifestyle category, a podcast nickname, and a subscription plan before anyone has decent human data.

GLP-1s went from niche research topic to brunch conversation overnight. Science, as usual, lags.

Why is “microdosing” GLP-1s suddenly being treated like a safer version of standard dosing? Lower dose can mean fewer side effects, sure, but it doesn’t automatically make the approach well studied or prevent muscle loss. The trend seems to be moving faster than the actual evidence, especially among people using it for vague “metabolic optimization.”

Comparing BPC-157 with TB-500, I keep seeing people treat them as interchangeable for tendon recovery, but the proposed mechanisms and evidence aren’t really the same. Has anyone found a decent human study or even a clear reason to prefer one over the other, rather than just repeating vendor anecdotes? Trying to separate plausible biology from peptide folklore.